Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Jun;35(6):1208–1213. doi: 10.1128/aac.35.6.1208

Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats.

R M Fielding 1, P C Smith 1, L H Wang 1, J Porter 1, L S Guo 1
PMCID: PMC284312  PMID: 1929263

Abstract

The pharmacokinetics and tissue distribution of two amphotericin B dosage forms were compared in rats. A novel lipid-based colloidal delivery system for amphotericin B (Amphotericin B Colloidal Dispersion [ABCD]) which reduces the toxicity of amphotericin B in animals was compared with a conventional micellar formulation. Male Sprague-Dawley rats received a single intravenous injection of 1.0 mg of ABCD, 5.0 mg of ABCD, or 1.0 mg of micellar amphotericin B per kg. Plasma and tissue samples were obtained at 0.5 to 96 h after dosing and analyzed for amphotericin B by high-pressure liquid chromatography. Animals receiving ABCD demonstrated reduced peak levels in plasma, a three- to sevenfold reduction in amphotericin B delivery to the kidneys (the major target organ for toxicity), and prolonged residence time compared with those receiving the micellar formulation. In contrast, amphotericin B concentrations in the liver were two- to threefold higher with ABCD than with the micellar formulation: nearly 100% of the amphotericin B administered as ABCD was recovered from the liver 30 min after dosing. These results suggest that the colloidal particles of ABCD are taken up by the liver, which then acts as a reservoir of amphotericin B.

Full text

PDF
1208

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmad I., Sarkar A. K., Bachhawat B. K. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B. Indian J Biochem Biophys. 1989 Dec;26(6):351–356. [PubMed] [Google Scholar]
  2. Bindschadler D. D., Bennett J. E. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis. 1969 Oct;120(4):427–436. doi: 10.1093/infdis/120.4.427. [DOI] [PubMed] [Google Scholar]
  3. Brajtburg J., Elberg S., Bolard J., Kobayashi G. S., Levy R. A., Ostlund R. E., Jr, Schlessinger D., Medoff G. Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis. 1984 Jun;149(6):986–997. doi: 10.1093/infdis/149.6.986. [DOI] [PubMed] [Google Scholar]
  4. Brajtburg J., Powderly W. G., Kobayashi G. S., Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother. 1990 Feb;34(2):183–188. doi: 10.1128/aac.34.2.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brajtburg J., Powderly W. G., Kobayashi G. S., Medoff G. Amphotericin B: delivery systems. Antimicrob Agents Chemother. 1990 Mar;34(3):381–384. doi: 10.1128/aac.34.3.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Edmonds L. C., Davidson L., Bertino J. S., Jr Solubility and stability of amphotericin B in human serum. Ther Drug Monit. 1989;11(3):323–326. doi: 10.1097/00007691-198905000-00015. [DOI] [PubMed] [Google Scholar]
  7. Gallis H. A., Drew R. H., Pickard W. W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990 Mar-Apr;12(2):308–329. doi: 10.1093/clinids/12.2.308. [DOI] [PubMed] [Google Scholar]
  8. Graybill J. R., Craven P. C. Antifungal agents used in systemic mycoses. Activity and therapeutic use. Drugs. 1983 Jan;25(1):41–62. doi: 10.2165/00003495-198325010-00003. [DOI] [PubMed] [Google Scholar]
  9. Graybill J. R., Craven P. C., Taylor R. L., Williams D. M., Magee W. E. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis. 1982 May;145(5):748–752. doi: 10.1093/infdis/145.2.748. [DOI] [PubMed] [Google Scholar]
  10. Hulse M., Feldman S., Bruckner J. V. Effect of blood sampling schedules on protein drug binding in the rat. J Pharmacol Exp Ther. 1981 Aug;218(2):416–420. [PubMed] [Google Scholar]
  11. Kim H., Loebenberg D., Marco A., Symchowicz S., Lin C. Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother. 1984 Oct;26(4):446–449. doi: 10.1128/aac.26.4.446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lopez-Berestein G., Rosenblum M. G., Mehta R. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv. 1984 Summer;1(3):199–205. doi: 10.1089/cdd.1984.1.199. [DOI] [PubMed] [Google Scholar]
  13. Moghimi S. M., Patel H. M. Differential properties of organ-specific serum opsonins for liver and spleen macrophages. Biochim Biophys Acta. 1989 Sep 18;984(3):379–383. doi: 10.1016/0005-2736(89)90306-4. [DOI] [PubMed] [Google Scholar]
  14. Parekh A. C., Creno R. J., Dave C. V. Hypocholesterolemic effect of amphotericin B: an analytical approach. Res Commun Chem Pathol Pharmacol. 1974 Oct;9(2):307–314. [PubMed] [Google Scholar]
  15. Patterson T. F., Andriole V. T. The role of liposomal amphotericin B in the treatment of systemic fungal infections. Eur J Cancer Clin Oncol. 1989;25 (Suppl 2):S63–S68. [PubMed] [Google Scholar]
  16. Sarosi G. A. Amphotericin B. Still the 'gold standard' for antifungal therapy. Postgrad Med. 1990 Jul;88(1):151-2, 155-61, 165-6. doi: 10.1080/00325481.1990.11716368. [DOI] [PubMed] [Google Scholar]
  17. Sculier J. P., Coune A., Meunier F., Brassinne C., Laduron C., Hollaert C., Collette N., Heymans C., Klastersky J. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol. 1988 Mar;24(3):527–538. doi: 10.1016/s0277-5379(98)90033-5. [DOI] [PubMed] [Google Scholar]
  18. Taylor R. L., Williams D. M., Craven P. C., Graybill J. R., Drutz D. J., Magee W. E. Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis. 1982 May;125(5):610–611. doi: 10.1164/arrd.1982.125.5.610. [DOI] [PubMed] [Google Scholar]
  19. Vecchiarelli A., Verducci G., Perito S., Puccetti P., Marconi P., Bistoni F. Involvement of host macrophages in the immunoadjuvant activity of amphotericin B in a mouse fungal infection model. J Antibiot (Tokyo) 1986 Jun;39(6):846–855. doi: 10.7164/antibiotics.39.846. [DOI] [PubMed] [Google Scholar]
  20. Wasan K. M., Vadiei K., Lopez-Berestein G., Luke D. R. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J Infect Dis. 1990 Mar;161(3):562–566. doi: 10.1093/infdis/161.3.562. [DOI] [PubMed] [Google Scholar]
  21. Wolf J. E., Massof S. E. In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B. Infect Immun. 1990 May;58(5):1296–1300. doi: 10.1128/iai.58.5.1296-1300.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES